Operating
Equity Securities, FV-NI, Gain (Loss)
Alnylam Pharmaceuticals Equity Securities, FV-NI, Gain (Loss) increased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from -$956.00K to $0.00. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase indicates positive market performance of held securities, while a decrease reflects market volatility or investment underperformance.
Detailed definition
Represents the unrealized or realized gains and losses on equity investments measured at fair value through net income....
Peer comparison
Common in companies with significant treasury or strategic investment portfolios; peers often report this as a non-operating adjustment.
Metric ID:
operating_equity_securities_fv_ni_gain_lossHistorical Data
13 periods
| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $18.69M | -$31.16M | -$1.10M | -$7.85M | -$2.27M | -$16.84M | $78.00K | -$1.37M | -$1.57M | -$166.00K | -$956.00K | -$1.35M | $0.00 |
| QoQ Change | — | -266.7% | +96.5% | -615.6% | +71.1% | -643.0% | +100.5% | <-999% | -14.6% | +89.4% | -475.9% | -41.2% | +100.0% |
| YoY Change | — | — | — | -142.0% | +92.7% | -114.6% | +103.4% | — | +90.7% | — | <-999% | +1.2% | +100.0% |
Range-$31.16M – $18.69M
CAGR-100.0%
Avg YoY Growth-149.3%
Median YoY Growth+46.0%
Equity Securities, FV-NI, Gain (Loss) at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's equity securities, fv-ni, gain (loss)?
- Alnylam Pharmaceuticals (ALNY) reported equity securities, fv-ni, gain (loss) of $0.00 in Q1 2026.
- How has Alnylam Pharmaceuticals's equity securities, fv-ni, gain (loss) changed year-over-year?
- Alnylam Pharmaceuticals's equity securities, fv-ni, gain (loss) increased by 100.0% year-over-year, from -$956.00K to $0.00.
- What does equity securities, fv-ni, gain (loss) mean?
- The net gain or loss from changes in the market value of equity investments.